Targeting the interleukin 6 receptor to treat neuromyelitis optica

JAMA Neurology

Volumn 72, Issue 7, 2015, Pages 747-748

  Irani, Sarosh R ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINOCICEPTIVE AGENT; AQUAPORIN 4 ANTIBODY; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ALLODYNIA; ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HOSPITALIZATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DIFFERENTIATION; MYELOOPTIC NEUROPATHY; NEUROPATHIC PAIN; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PLASMABLAST; PLASMAPHERESIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; FEMALE; NEUROMYELITIS OPTICA;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; NEUROMYELITIS OPTICA; RECEPTORS, INTERLEUKIN-6;

EID: 84937605007     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0579     Document Type: Editorial

References (10)

1. Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica: prevalence, pathogenesis and therapy. Nat Rev Neurol. 2014;10(9):529-536.
2. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.Brain. 2008;131(pt 11):3072-3080.
3. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad SciUSA. 2011;108(9):3701-3706.
4. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology.2014; 82(15):1302-1306.
5. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.JAMA Neurol. 2013;70(3):394-397.
6. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder [published online May 18, 2015]. JAMA Neurol. doi:10.1001/jamaneurol.2015.0533.
7. Smolen JS, Beaulieu A, Rubbert-Roth A, et al OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997.
8. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015;21(6):1248-1257.
9. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC; Canadian Cooperation MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology. 1990;40(6):971-975.
10. Gruol DL, Puro A, Hao C, Blakely P, Janneke E, Vo K. Neuroadaptive changes in cerebellar neurons induced by chronic exposure to IL-6. J Neuroimmunol. 2011;239(1-2):28-36.